Birmingham Bruce K, Bujac Sarah R, Elsby Robert, Azumaya Connie T, Wei Cheryl, Chen Yusong, Mosqueda-Garcia Rogelio, Ambrose Helen J
AstraZeneca, Wilmington, DE, USA,
Eur J Clin Pharmacol. 2015 Mar;71(3):341-55. doi: 10.1007/s00228-014-1801-z. Epub 2015 Feb 12.
Systemic exposure to rosuvastatin is approximately double that of Caucasians in Asian subjects. We investigated whether this pattern of increased exposure exists for other statins.
Plasma exposure following single-dose rosuvastatin 20 mg, atorvastatin 40 mg or simvastatin 40 mg was studied in Chinese, Japanese and Caucasian subjects. Plasma concentrations were determined using LC-MS methods. Impact of polymorphisms in SLCO1B1 (T521>C and A388>G) and in ABCG2 (C421>A) on exposure to rosuvastatin, atorvastatin, simvastatin and simvastatin acid was assessed.
Relative to Caucasians, geometric mean area under the curve from time zero to time of last quantifiable concentration was 86 % (90 % confidence interval (CI), 51-130 %) and 55 % (26-91 %) higher for rosuvastatin in Chinese and Japanese subjects, respectively, 53 % (25-88 %) and 69 % (37-108 %) higher for atorvastatin, 23 % (0-52 %) and 12 % (-0.9-39 %) higher for simvastatin and 28 % (5-56 %) and 34 % (10-64 %) higher for simvastatin acid. Geometric mean maximum drug concentration was also proportionally higher for each statin. Polymorphisms in SLCO1B1 T521>C or ABCG2 C421>A were associated with higher exposure to rosuvastatin, atorvastatin and simvastatin acid (but not simvastatin) within a population, but only the ABCG2 C421>A polymorphism contributed towards between-population exposure differences. In individuals carrying wild-type alleles for both SLCO1B1 and ABCG2, area under the plasma concentration-time curve (AUC) still appeared to be higher for rosuvastatin, atorvastatin and simvastatin acid in Chinese and Japanese subjects compared with Caucasians, respectively.
Increased exposure to statins in Asian subjects versus Caucasians may represent a more general class phenomenon than previously recognized.
亚洲受试者中瑞舒伐他汀的全身暴露量约为白种人的两倍。我们研究了其他他汀类药物是否也存在这种暴露增加的模式。
在中国、日本和白种人受试者中研究了单剂量20毫克瑞舒伐他汀、40毫克阿托伐他汀或40毫克辛伐他汀后的血浆暴露情况。使用液相色谱-质谱法测定血浆浓度。评估了溶质载体有机阴离子转运体1B1(SLCO1B1,T521>C和A388>G)及ATP结合盒转运体G2(ABCG2,C421>A)基因多态性对瑞舒伐他汀、阿托伐他汀、辛伐他汀及辛伐他汀酸暴露量的影响。
与白种人相比,中国和日本受试者中瑞舒伐他汀从零时到最后可定量浓度时的曲线下面积几何均值分别高86%(90%置信区间[CI],51-130%)和55%(26-91%),阿托伐他汀分别高53%(25-88%)和69%(37-108%),辛伐他汀分别高23%(0-52%)和12%(-0.9-39%),辛伐他汀酸分别高28%(5-56%)和34%(10-64%)。每种他汀类药物的最大血药浓度几何均值也相应更高。SLCOIB1基因T521>C或ABCG2基因C421>A多态性与人群中瑞舒伐他汀、阿托伐他汀及辛伐他汀酸(而非辛伐他汀)的较高暴露相关,但只有ABCG2基因C421>A多态性导致了人群间的暴露差异。在SLCO1B1和ABCG2均携带野生型等位基因的个体中,中国和日本受试者中瑞舒伐他汀、阿托伐他汀及辛伐他汀酸的血浆浓度-时间曲线下面积(AUC)与白种人相比似乎仍较高。
与白种人相比,亚洲受试者中他汀类药物暴露增加可能是一种比此前认识到的更为普遍的类别现象。